Literature DB >> 7710716

Autoimmune hemolytic anemia.

S Izui1.   

Abstract

Autoimmune hemolytic anemia (AHA) is characterized by the production of Coombs' antibodies, which are responsible for the destruction of red blood cells (RBCs). Analysis of both monoclonal anti-RBC autoantibodies derived from autoimmune New Zealand black mice and transgenic mice expressing a pathogenic IgM anti-RBC autoantibody has considerably improved our understanding of the B-cell responses involved in AHA, although our knowledge of T-cell immunity in AHA is still limited. The identification of the major T-cell epitope in the context of MHC class II molecules would be of paramount importance in helping to elucidate the cellular and molecular basis central to the development of AHA.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7710716     DOI: 10.1016/0952-7915(94)90015-9

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  4 in total

1.  Immune complex-like moieties in immunoglobulin for intravenous use (i.v.Ig) bind complement and enhance phagocytosis of human erythrocytes.

Authors:  H Shoham-Kessary; Y Naot; H Gershon
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

Review 2.  Oxidative stress as a potential causal factor for autoimmune hemolytic anemia and systemic lupus erythematosus.

Authors:  Junichi Fujii; Toshihiro Kurahashi; Tasuku Konno; Takujiro Homma; Yoshihito Iuchi
Journal:  World J Nephrol       Date:  2015-05-06

3.  Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice.

Authors:  Varsha Kumar; Syed R Ali; Stephanie Konrad; Jörg Zwirner; J Sjef Verbeek; Reinhold E Schmidt; J Engelbert Gessner
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

4.  Multiple loci are linked with anti-red blood cell antibody production in NZB mice -- comparison with other phenotypes implies complex modes of action.

Authors:  N J Lee; R J Rigby; H Gill; J J Boyle; L Fossati-Jimack; B J Morley; T J Vyse
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.